ArticleBMC neurology2026
Screening for neuronal antibodies in cognitive impairment and dementia clinics: a prospective multicenter study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAIE can sometimes present as chronic and insidious, whereas some dementia patients develop symptoms at a young age or experience rapid cognitive decline. We aimed to assess the prevalence of antibody-mediated encephalitis in outpatients presenting with cognitive impairment.
methodsOne hundred ten Thai volunteers were recruited from three tertiary care centers: 23 patients with dementia and 87 patients with MCI. Serological tests for neuronal antibodies and Hashimoto’s antibodies (anti-TPO and anti-TG) were performed.
resultsThe mean age of the participants was 68.82 ± 6.08 years, with a female-to-male ratio of 2.3:1. The onset of memory impairment was approximately 36 months (range from 0 to 180 months). Sixteen patients (14.5%) had abnormal blood tests, including 15 (13.6%) with Hashimoto’s antibodies and one (0.9%) with anti-LGI1. However, anti-TPO and anti-TG levels were significantly elevated in only 5 patients (4.5%). At the 1-year follow-up, 3 patients still had elevated levels of Hashimoto’s antibodies, while 1 patient with an anti-LGI1 antibody was repeatedly negative. All participants had no other symptoms that fulfilled the diagnostic criteria for Hashimoto’s encephalitis or AIE.
conclusionsBroad neuronal antibody screening appears to have low diagnostic yield and limited additional value in patients in their 60s with symptoms of cognitive impairment lasting longer than 36 months and without other significant neurological signs. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.